focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Indeed another great RNS, excellent progress and run by a sensible Board. Onwards and Upwards one hopes. Come on the elusive 75p!
Would be nice to know... someone is taking a position. Helped drive the price up. Surprised it didn't spike more as this seems very tightly held.
It does feel like the mkt priced this in already. It's good progress, sensible bank debt reduction, controlled and in safe hands. Undervalued imo but great news on the dividend front. Feels like a safe longer term hold for me still. Happy to sit and wait for the upside.
The Mission Marketing Group plc Interim results for the six months to 30 June 2017 The Mission Marketing Group plc ("TMMG" or "the missiontm"), the marketing communications and advertising group, sets out its unaudited interim results for the six months ended 30 June 2017. Highlights · Good organic growth from the Group's core business · Some great new business wins in the period, including Mars, Neff, Reckitt Benckiser, Revlon, The Royal Mint and Universal Studios · Recently acquired RJW trading well · fuse now officially launched · Mongoose Sports and April Six Asia start-up ventures moved into profitability Financial · Revenue up 4% to £33.8m (2016: £32.4m) · Like-for-like revenue up 6% in Branding, Advertising and Digital · Headline profit before tax up 11% to £2.9m (2016: £2.6m) · Headline diluted EPS up 11% to 2.58 pence (2016: 2.33 pence) · A strong second-half bias again predicted · Cash inflows from operating activities of £5.8m (2016: £4.8m) · Net bank debt reduced by £2.1m in the six months after settling prior and new acquisition obligations Dividend · Interim dividend increased by 10% to 0.55p (2016: 0.5p) · Payable on 1 December 2017 to shareholders on the register at 3 November 2017 David Morgan, Chairman, commented: "With our business becoming stronger, including good growth from our core business, we have a great platform from which to grow. We will continue to target further margin improvements, seek new opportunities, drive into new markets and upskill our offering. We again expect a strong second half to the year and are confident that we will deliver another year of growth."
It's someone with more funds than I !!! Hope you're well. Rgds
The Mission Marketing Group plc Trading update and notice of results The Mission Marketing Group plc ('the missiontm', or "the Group" AIM: TMMG), the marketing communications and advertising group, today issues a trading update for the six months ended 30 June 2017. The Board is pleased to report that trading is in line with expectations and, for the first half of 2017, we again expect double digit growth in headline profit before tax. The Group's net debt fell £2.0m after making acquisition consideration payments totalling £3.7m in the period, reflecting strong working capital inflows. Net debt was £9.3m at 30 June 2017 and the Group's leverage ratios (the ratios of net bank debt and total debt to EBITDA) again reduced during the six month period and remain comfortably within the limits set by the Board for these key performance indicators. In common with recent years, we expect our results for the year to 31 December 2017 to again have a significant bias towards the second half and we look forward to further progress over the remainder of the year. The Group expects its interim results, for the six months ended 30 June 2017, to be announced on 21 September.
Looks like it'll finish down in the US tonight...
Company Verona Pharma plc TIDM VRP Headline Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference Released 13:30 23-May-2017 Number HUG2107066 May 23, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference. An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Close at 15.375pc up.
I'm showing the DRs up 12% 1.65usd so looking good right now. Nice move for a change
Nothing really not to like here except the share price... roll on 75p!
Looks like will be 8:1 ratio I agree
I should think if $13.49 is the ADS Px then 13.49/1.2398 exch rate equals £10.88 then divide by current share price 1.325 is 8.2 ordinary shares. Sound right?
Too many years in the waiting for me! Been long and wrong here for a while. Let's hope this is our year for all our sakes
Verona Pharma Appoints Richard Hennings as Commercial Director; Enters into Collaborations to Develop Dry Powder and Metered Dose Inhaler Formulations for COPD Maintenance Treatment Richard Hennings brings more than a decade of strategic commercial biopharma leadership Development of RPL554 in dry powder and metered dose inhaler formulations has potential to increase commercial market opportunity 31 March 2017, London - Verona Pharma plc (AIM: VRP.L) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announced today the appointment of Richard Hennings to the Company's senior management team as Commercial Director, with immediate effect. Richard will oversee the Company's market access strategy and its increasing commercial focus. As part of this, Verona Pharma has also announced new collaborations with two European technology companies to develop its first-in-class product candidate RPL554 as dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for maintenance treatment of chronic obstructive pulmonary disease (COPD). DPI and MDI devices are the most common forms of drug delivery in non-hospitalized patients with COPD and are well-suited for the maintenance therapy of COPD patients. With more than 15 years in the healthcare industry, Richard has held a series of roles with increasing responsibility, including leading the commercialisation of certain innovative medicines, strategy development and local operational execution. His experience spans a number of top global pharmaceutical and biotechnology companies, including AstraZeneca, Gilead Sciences (Gilead) and Novartis. During his tenure at Gilead, Richard was involved in growing Gilead's respiratory development portfolio to include cystic fibrosis and COPD development programmes. In addition, the Company believes its new collaborations to develop RPL554 in DPI and MDI formulations have the potential to increase the market opportunity for the product, if approved. Handheld DPI and MDI devices are the most common forms of drug delivery in non-hospitalized patients with COPD and are well suited for maintenance therapy. Following the development of commercially viable formulations, Verona Pharma plans to commence pre-clinical studies with the DPI and MDI formulations and may also explore the potential use of the formulation for the treatment of asthma and other respiratory diseases. "We are delighted to welcome Richard to the Verona Pharma team and look forward to advancing our market focus and commercial plans under his leadership. Richard brings extensive experience in commercial planning and launch preparations, as well as brand building of innovative respiratory products in the U.S. and Europe." said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. "In addition, we believe our new co
There is a lot in there to ponder
Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554 Establishes research and operational platform for clinical trials covering COPD and Cystic Fibrosis 22 March 2017, London - Verona Pharma plc (AIM: VRP.L) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, today announced it has entered into a global strategic services agreement with QuintilesIMS, a leading provider of biopharmaceutical development and commercial outsourcing services. The services agreement establishes an operational platform to facilitate Verona Pharma’s global clinical trial-related activities for the development of its product candidate RPL554 for the treatment of COPD (chronic obstructive pulmonary disease) and cystic fibrosis and for future commercialisation initiatives. Pursuant to the agreement, Quintiles will serve as sole provider of core clinical trial services for Verona Pharma’s RPL554 clinical development programs. Verona Pharma will have full access to Quintiles’ therapeutic and operational experts throughout the duration of each trial, from the planning and design through to execution. Joint governance and quality oversight has been established to ensure strategic and operational goals are met and compliance with regulatory and quality requirements. Verona Pharma will also have access to QuintilesIMS’ global commercial insights when developing its market access strategy in the United States for RPL554. Verona Pharma’s product candidate, RPL554, is an inhaled, dual PDE3/PDE4 inhibitor that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is currently developing RPL554 for the maintenance treatment of COPD patients and as an add-on therapy to commonly used therapies for the treatment of hospitalized patients with acute exacerbations of COPD. It is also developing RPL554 for the treatment of patients with cystic fibrosis. Dr Jan-Anders Karlsson, Verona Pharma’s Chief Executive Officer, commented, “Verona Pharma is focused on advancing the clinical development of RPL554 for the treatment of COPD and cystic fibrosis. The Company has already completed eight Phase 1 and 2a clinical trials for RPL554, and we believe that our strategic services agreement with QuintilesIMS will enhance the agility, productivity and commercial viability of our development activities as we progress multiple larger and later stage clinical trials.”
Director buy rns 20k shs
The Mission Marketing Group plc ('the missiontm' or "the Company", AIM: TMMG), the marketing communications and advertising group, announces the formation of a new management retention and incentive scheme, as communicated in the Company's trading update of 19 January 2017. The Growth Share Scheme Arrangement (the "Scheme") has been designed to further increase cross-selling incentives between the missiontm's agencies and focus on driving the group forward and increasing shareholder value. The Scheme has been designed to retain and incentivise those key people who it is believed will be crucial to the missiontm's long term ambitions, and only has value to the participants if the share price of the Company increases substantially. The Scheme Under the Scheme, individuals are invited to subscribe for shares in The Mission Marketing Holdings Limited ("A Shares"). These shares are subscribed for at a nominal value of 0.01p per A Share and will only have a material value if the Company's share price equals or exceeds 75p for at least 15 days over the next three years* ("Vesting Conditions"). If the Vesting Conditions are met the individuals will be entitled to exchange their A Shares for an equivalent number of Ordinary Shares of 10p each in the Capital of the Company ("Ordinary Shares"). The A Shares have no value if the Vesting Conditions are not met. To achieve the Vesting Conditions, the share price of the Company needs to increase by 83% from its current level, representing an increase in market capitalisation of approximately £29m. Under the Scheme, the A Shares would have an aggregate value at this level of approximately £4.3m and would be exchanged for 5,720,176 Ordinary Shares. The total number of Ordinary Shares under the Scheme and under existing options schemes is 8.36m, representing 9.9% of the issued Ordinary Share capital. In total, 5,720,171 A Shares were subscribed for on 21 February 2017 (the "Award") by a limited number of board members and non-PDMR key managers. The subscription details for board members of the missiontm are detailed below.
Reaction.... such a good company so undervalued